Helen Torley Sells 20,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $69.69, for a total value of $1,393,800.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $53,506,588.20. This represents a 2.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Helen Torley also recently made the following trade(s):

• On Wednesday, March 4th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $70.21, for a total transaction of $702,100.00.
• On Thursday, February 5th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $78.64, for a total transaction of $786,400.00.
• On Tuesday, February 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $76.12, for a total transaction of $1,522,400.00.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $67.36 on Friday. The company has a 50 day simple moving average of $72.69 and a two-hundred day simple moving average of $70.73. Halozyme Therapeutics, Inc. has a fifty-two week low of $47.50 and a fifty-two week high of $82.22. The company has a market capitalization of $7.95 billion, a price-to-earnings ratio of 27.05, a P/E/G ratio of 0.28 and a beta of 0.98. The company has a debt-to-equity ratio of 43.89, a quick ratio of 3.66 and a current ratio of 4.66.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The company had revenue of $451.77 million during the quarter, compared to the consensus estimate of $446.13 million. During the same period in the prior year, the firm earned $1.26 earnings per share. The business’s revenue for the quarter was up 51.6% compared to the same quarter last year. Analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of HALO. Root Financial Partners LLC bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at about $25,000. Measured Wealth Private Client Group LLC boosted its holdings in shares of Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 124 shares during the last quarter. Larson Financial Group LLC boosted its holdings in shares of Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 343 shares during the last quarter. Richardson Financial Services Inc. grew its position in Halozyme Therapeutics by 87.6% during the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 198 shares during the period. Finally, Newbridge Financial Services Group Inc. purchased a new stake in Halozyme Therapeutics during the second quarter valued at approximately $32,000. Institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on HALO shares. Weiss Ratings lowered Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Tuesday, February 24th. Wells Fargo & Company lifted their target price on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. TD Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Wall Street Zen cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Saturday, February 21st. Finally, Benchmark boosted their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Six equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $78.56.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.